| March 12th, 2025 |
Sirius Therapeutics Announces EMA Submission to Initiate a Phase 2 Clinical Trial of SRSD107, a Long–Acting, Next-Generation Anticoagulant for Thromboembolic Disorders |
| December 31st, 2024 |
Sirius Therapeutics Submits IND Application to NMPA for Another Novel siRNA Therapy |
| December 10th, 2024 |
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders |
| December 03rd, 2024 |
Sirius Therapeutics to Present Data from Its Phase 1 Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders at the 66th ASH Annual Meeting and Exposition |
| July 11th, 2024 |
Sirius Therapeutics Completes Enrollment in Phase 1 Trial of SRSD107, a First-in-Class siRNA Being Developed for Anticoagulant |
| July 09th, 2024 |
Sirius Therapeutics Appoints Patrick Yue, MD, as Chief Medical Officer |
| April 01st, 2024 |
Sirius Therapeutics Announces Dosing of First Subject in Chinese Phase 1 Clinical Trial of FXI siRNA Anticoagulant |
| March 22nd, 2024 |
Sirius Completes Enrollment in Phase 1 Trial of a PCSK9 siRNA |
| March 05th, 2024 |
Sirius Therapeutics Announces China NMPA Approval for Human Clinical Trial of SRSD107, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders |
| February 02nd, 2024 |
Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders |
